{"pmid":32333857,"title":"COVID-19 in Pregnancy: Consider Thromboembolic Disorders and Thromboprophylaxis.","text":["COVID-19 in Pregnancy: Consider Thromboembolic Disorders and Thromboprophylaxis.","Am J Obstet Gynecol","Di Renzo, Gian Carlo","Giardina, Irene","32333857"],"journal":"Am J Obstet Gynecol","authors":["Di Renzo, Gian Carlo","Giardina, Irene"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333857","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ajog.2020.04.017","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Thromboprophylaxis"],"_version_":1665071049706831872,"score":8.518259,"similar":[{"pmid":32330428,"title":"Hospital-based use of thromboprophylaxis in patients with COVID-19.","text":["Hospital-based use of thromboprophylaxis in patients with COVID-19.","Lancet","Spyropoulos, Alex C","Ageno, Walter","Barnathan, Elliot S","32330428"],"journal":"Lancet","authors":["Spyropoulos, Alex C","Ageno, Walter","Barnathan, Elliot S"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330428","week":"202017|Apr 20 - Apr 26","doi":"10.1016/S0140-6736(20)30926-0","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664996914744000512,"score":67.83695},{"pmid":32294289,"title":"Venous thromboembolism in COVID-19 patients.","text":["Venous thromboembolism in COVID-19 patients.","We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days.","J Thromb Haemost","Porfidia, Angelo","Pola, Roberto","32294289"],"abstract":["We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days."],"journal":"J Thromb Haemost","authors":["Porfidia, Angelo","Pola, Roberto"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294289","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14842","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Enoxaparin","Heparin"],"_version_":1664636192702857216,"score":54.254475},{"pmid":32277760,"title":"Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis.","text":["Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis.","Swiss Med Wkly","Casini, Alessandro","Alberio, Lorenzo","Angelillo-Scherrer, Anne","Fontana, Pierre","Gerber, Bernhard","Graf, Lukas","Hegemann, Inga","Korte, Wolfgang","Kremer Hovinga, Johanna","Lecompte, Thomas","Martinez, Maria","Nagler, Michael","Studt, Jan-Dirk","Tsakiris, Dimitrios","Wuillemin, Walter","Asmis, Lars","32277760"],"journal":"Swiss Med Wkly","authors":["Casini, Alessandro","Alberio, Lorenzo","Angelillo-Scherrer, Anne","Fontana, Pierre","Gerber, Bernhard","Graf, Lukas","Hegemann, Inga","Korte, Wolfgang","Kremer Hovinga, Johanna","Lecompte, Thomas","Martinez, Maria","Nagler, Michael","Studt, Jan-Dirk","Tsakiris, Dimitrios","Wuillemin, Walter","Asmis, Lars"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277760","week":"202015|Apr 06 - Apr 12","doi":"10.4414/smw.2020.20247","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Thromboprophylaxis","Swiss"],"countries":["Switzerland"],"countries_codes":["CHE|Switzerland"],"_version_":1664636943966666752,"score":53.85007},{"pmid":32305399,"pmcid":"PMC7162752","title":"COVID-19 and diabetes management: What should be considered?","text":["COVID-19 and diabetes management: What should be considered?","Diabetes Res Clin Pract","Ceriello, Antonio","Stoian, Anca Pantea","Rizzo, Manfredi","32305399"],"journal":"Diabetes Res Clin Pract","authors":["Ceriello, Antonio","Stoian, Anca Pantea","Rizzo, Manfredi"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305399","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.diabres.2020.108151","keywords":["covid-19","cardiovascular disease","dpp4","diabetes","glp-1ra","hydroxychloroquine","pioglitazone","sglt-2"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664641855728386048,"score":49.126022},{"pmid":32305585,"title":"Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 Pandemic.","text":["Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 Pandemic.","A markedly increased demand for vascular ultrasound laboratory and other imaging studies in COVID-19 positive patients has occurred, due to most with markedly elevated D-dimer, and a presumed prothrombotic state in many of the very ill patients. This article summarizes a broad institutional consensus focusing on evaluation and recommended empirical therapy for COVID-19 positive patients. We recommend following the algorithms with the idea that as more data becomes available that this may well change.","J Vasc Surg Venous Lymphat Disord","Obi, Andrea T","Barnes, Geoff D","Wakefield, Thomas W","Brown Rvt, Sandra","Eliason, Jonathon L","Arndt, Erika","Henke, Peter K","32305585"],"abstract":["A markedly increased demand for vascular ultrasound laboratory and other imaging studies in COVID-19 positive patients has occurred, due to most with markedly elevated D-dimer, and a presumed prothrombotic state in many of the very ill patients. This article summarizes a broad institutional consensus focusing on evaluation and recommended empirical therapy for COVID-19 positive patients. We recommend following the algorithms with the idea that as more data becomes available that this may well change."],"journal":"J Vasc Surg Venous Lymphat Disord","authors":["Obi, Andrea T","Barnes, Geoff D","Wakefield, Thomas W","Brown Rvt, Sandra","Eliason, Jonathon L","Arndt, Erika","Henke, Peter K"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305585","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jvsv.2020.04.009","keywords":["anticoagulant","deep venous thrombosis","duplex ultrasound","pulmonary embolism","venous thromboembolism"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1664641855752503296,"score":45.76857}]}